August 7, 2024 07:08 AM EDTUpdated 09:06 AM
R&D
Pharma

Up­dat­ed: No­vo Nordisk yanks We­govy fil­ing for heart fail­ure from FDA, will re­sub­mit next year

Reynald Castañeda

Deputy Editor

No­vo Nordisk is run­ning in­to a speed bump with We­govy’s la­bel ex­pan­sion ef­forts in heart dis­ease as it has pulled its FDA sub­mis­sion in heart …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times